Observational studyMedicine2026
Factors associated with elevated serum IgG4 in rheumatic diseases: A retrospective single-center observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated serum immunoglobulin G4 (IgG4) levels have been reported in various rheumatic diseases; however, the factors associated with IgG4 elevation remain incompletely understood. This study aimed to evaluate the frequency of elevated serum IgG4 in different rheumatic diseases and to explore its association with disease classification based on typical inflammatory characteristics and autoantibody status. This retrospective single-center study included 255 patients with rheumatic diseases who underwent serum IgG4 testing between January 2017 and December 2022. Patients were categorized for exploratory disease-level analyses according to their typical association with elevated C-reactive protein (CRP) levels (rheumatoid arthritis [RA], spondyloarthritis, vasculitis, and adult-onset Still disease) or without prominent CRP elevation (Sjögren syndrome, systemic lupus erythematosus, retroperitoneal fibrosis, idiopathic inflammatory myopathy, and undifferentiated connective tissue disease), as well as according to the presence or absence of disease-specific autoantibodies. The frequency of elevated serum IgG4 (≥1.35 g/L) was compared between groups. Elevated IgG4 was more frequently observed in patients with RA than in those with Sjögren syndrome (30.36% vs 11.83%, P = .005). Rheumatic diseases classified as CRP-associated demonstrated a higher frequency of elevated IgG4 than non-CRP-associated diseases (30.23% vs 14.20%, P < .001). Among patients with RA, elevated IgG4 was associated with higher levels of immunoglobulin M, immunoglobulin G, CRP, erythrocyte sedimentation rate, and Disease Activity Score 28-CRP scores (all P < .05). In this retrospective cohort, elevated serum IgG4 was more frequently observed in rheumatic diseases classified as CRP-associated than in non-CRP-associated diseases. No significant association was observed between elevated serum IgG4 frequency and autoantibody status. These findings demonstrate an association between disease classification based on typical inflammatory characteristics and the frequency of elevated serum IgG4; however, prospective studies incorporating patient-level inflammatory assessments are required to determine the clinical significance of this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.